{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:24:15Z","timestamp":1772173455264,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1013417","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000}}],"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Gene signatures predictive of chemotherapeutic response have the potential to extend the reach of precision medicine by allowing oncologists to optimize treatment for individuals. Most published predictive signatures are only capable of predicting response for individual drugs, but most chemotherapy regimens utilize combinations of different agents. We propose a unified framework, called the chemogram, that uses predictive signatures to rank the relative predicted sensitivity of different drugs for individual tumors. Using this approach, providers could efficiently screen against many therapeutics to optimize chemotherapy at any time, whether it be for a treatment-naive tumor or a chemo-resistant tumor requiring a new treatment strategy. To demonstrate the utility of the chemogram, we used predictive signatures (extracted from a previously established method) in our framework to rank predicted sensitivity among drugs within cell lines. We then compared the rank order of predicted and observed response against each drug. Across most cancer types, chemogram-generated predictions were more accurate than predictions made by randomly generated gene signatures, signatures extracted from differential expression alone, and was comparable to another established method of drug response prediction. Our framework demonstrates the ability of transcriptomic signatures to not only predict chemotherapeutic response, but also correctly assign rankings of drug sensitivity on an individual basis. Additionally, scaling the chemogram to include more drugs does not compromise accuracy.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1013417","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T17:54:58Z","timestamp":1757526898000},"page":"e1013417","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Personalizing chemotherapy drug selection using a novel transcriptomic chemogram"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5671-0608","authenticated-orcid":true,"given":"Kristi","family":"Lin-Rahardja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Scarborough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-7673","authenticated-orcid":true,"given":"Jacob G.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"issue":"1","key":"pcbi.1013417.ref001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine","volume":"14","author":"E Fountzilas","year":"2022","journal-title":"Genome Med."},{"issue":"7","key":"pcbi.1013417.ref002","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.annonc.2021.04.003","article-title":"Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients 2006 -2020","volume":"32","author":"A Haslam","year":"2021","journal-title":"Ann Oncol."},{"issue":"11","key":"pcbi.1013417.ref003","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.trecan.2022.06.009","article-title":"Drug independence and the curability of cancer by combination chemotherapy","volume":"8","author":"AE Pomeroy","year":"2022","journal-title":"Trends Cancer."},{"issue":"4","key":"pcbi.1013417.ref004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/0255-0857.71802","article-title":"Hospital antibiogram: a necessity","volume":"28","author":"S Joshi","year":"2010","journal-title":"Indian J Med Microbiol."},{"key":"pcbi.1013417.ref005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41698-018-0060-3","article-title":"Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response","volume":"2","author":"R Vargas","year":"2018","journal-title":"NPJ Precis Oncol."},{"issue":"10","key":"pcbi.1013417.ref006","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1038\/s41596-020-0379-4","article-title":"Establishment of patient-derived cancer organoids for drug-screening applications","volume":"15","author":"E Driehuis","year":"2020","journal-title":"Nat Protoc."},{"issue":"1","key":"pcbi.1013417.ref007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13073-021-01000-y","article-title":"Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures","volume":"13","author":"C Suphavilai","year":"2021","journal-title":"Genome Med."},{"issue":"1","key":"pcbi.1013417.ref008","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1038\/s41467-022-33291-z","article-title":"Gene expression based inference of cancer drug sensitivity","volume":"13","author":"S Chawla","year":"2022","journal-title":"Nat Commun."},{"issue":"11","key":"pcbi.1013417.ref009","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.celrep.2019.11.017","article-title":"A deep learning framework for predicting response to therapy in cancer","volume":"29","author":"T Sakellaropoulos","year":"2019","journal-title":"Cell Reports."},{"issue":"7","key":"pcbi.1013417.ref010","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.3390\/ijms24076738","article-title":"Evolution-informed strategies for combating drug resistance in cancer","volume":"24","author":"K Lin-Rahardja","year":"2023","journal-title":"Int J Mol Sci."},{"issue":"1","key":"pcbi.1013417.ref011","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5644\/ama2006-124.239","article-title":"Prospective validation of a genomic assay in breast cancer: the 70-gene mammaprint assay and the MINDACT trial","volume":"48","author":"W Audeh","year":"2019","journal-title":"Acta Med Acad."},{"issue":"2","key":"pcbi.1013417.ref012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14740\/wjon1019w","article-title":"The era of multigene panels comes? The clinical utility of oncotype DX and MammaPrint","volume":"8","author":"L Xin","year":"2017","journal-title":"World J Oncol."},{"key":"pcbi.1013417.ref013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/IJWH.S124520","article-title":"Spotlight on the utility of the oncotype DX\u00ae breast cancer assay","volume":"10","author":"ZR Siow","year":"2018","journal-title":"Int J Womens Health."},{"key":"pcbi.1013417.ref014","doi-asserted-by":"crossref","unstructured":"Brawer MK, Cuzick JM, Cooperberg MR, Swanson GP, Freedland SJ, Reid JE. Prolaris: a novel genetic test for prostate cancer prognosis. 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.5005"},{"issue":"5","key":"pcbi.1013417.ref015","first-page":"311","article-title":"Prolaris test for prostate cancer risk assessment","volume":"100","author":"MH Ebell","year":"2019","journal-title":"Am Fam Physician."},{"key":"pcbi.1013417.ref016","article-title":"A 22 gene-expression assay, Decipher\u00ae (GenomeDx Biosciences) to predict five-year risk of metastatic prostate cancer in men treated with radical prostatectomy","volume":"7","author":"M Marrone","year":"2015","journal-title":"PLoS Curr."},{"issue":"1","key":"pcbi.1013417.ref017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41698-023-00375-y","article-title":"Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature","volume":"7","author":"JA Scarborough","year":"2023","journal-title":"NPJ Precis Oncol."},{"key":"pcbi.1013417.ref018","doi-asserted-by":"crossref","first-page":"863210","DOI":"10.1155\/2011\/863210","article-title":"Current therapeutic approaches in metastatic and recurrent ewing sarcoma","volume":"2011","author":"M Huang","year":"2011","journal-title":"Sarcoma."},{"key":"pcbi.1013417.ref019","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3389\/fonc.2019.01458","article-title":"Current and future treatment strategies for rhabdomyosarcoma","volume":"9","author":"C Chen","year":"2019","journal-title":"Frontiers in Oncology."},{"key":"pcbi.1013417.ref020","unstructured":"Lightfoot H, van der Meer D, Vis DJ. gdscIC50: pipeline for GDSC curve fitting. 2022."},{"issue":"7","key":"pcbi.1013417.ref021","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"ME Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"pcbi.1013417.ref022","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"D Maeser","year":"2021","journal-title":"Brief Bioinform."},{"issue":"12","key":"pcbi.1013417.ref023","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1101\/gr.124321.111","article-title":"Differential expression in RNA-seq: a matter of depth","volume":"21","author":"S Tarazona","year":"2011","journal-title":"Genome Res."},{"issue":"6","key":"pcbi.1013417.ref024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10522-018-9750-z","article-title":"Gene expression hallmarks of cellular ageing","volume":"19","author":"S Frenk","year":"2018","journal-title":"Biogerontology."},{"key":"pcbi.1013417.ref025","doi-asserted-by":"crossref","first-page":"106126","DOI":"10.1016\/j.cct.2020.106126","article-title":"Independent drug action and its statistical implications for development of combination therapies","volume":"98","author":"C Chen","year":"2020","journal-title":"Contemp Clin Trials."},{"issue":"12","key":"pcbi.1013417.ref026","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s43018-023-00667-z","article-title":"Additivity predicts the efficacy of most approved combination therapies for advanced cancer","volume":"4","author":"H Hwangbo","year":"2023","journal-title":"Nat Cancer."},{"issue":"7","key":"pcbi.1013417.ref027","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"AC Palmer","year":"2017","journal-title":"Cell."},{"issue":"1","key":"pcbi.1013417.ref028","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41467-020-16212-w","article-title":"Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures","volume":"11","author":"R Vander Velde","year":"2020","journal-title":"Nat Commun."},{"issue":"6","key":"pcbi.1013417.ref029","first-page":"488","article-title":"Local cancer recurrence: the realities, challenges, and opportunities for new therapies","volume":"68","author":"DA Mahvi","year":"2018","journal-title":"CA Cancer J Clin."},{"issue":"7","key":"pcbi.1013417.ref030","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s11538-018-0434-2","article-title":"Optimal therapy scheduling based on a pair of collaterally sensitive drugs","volume":"80","author":"N Yoon","year":"2018","journal-title":"Bull Math Biol."},{"issue":"5","key":"pcbi.1013417.ref031","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00285-021-01671-6","article-title":"Theoretical modeling of collaterally sensitive drug cycles: shaping heterogeneity to allow adaptive therapy","volume":"83","author":"N Yoon","year":"2021","journal-title":"J Math Biol."},{"issue":"10","key":"pcbi.1013417.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000515","article-title":"Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance","volume":"17","author":"J Maltas","year":"2019","journal-title":"PLoS Biol."},{"key":"pcbi.1013417.ref033","doi-asserted-by":"crossref","unstructured":"Weaver DT, Maltas J, Scott JG. Reinforcement learning informs optimal treatment strategies to limit antibiotic resistance. bioRxiv. 2023:2023-01.","DOI":"10.1101\/2023.01.12.523765"},{"key":"pcbi.1013417.ref034","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drup.2012.10.003","article-title":"Understanding resistance to combination chemotherapy","volume":"15","author":"JR Pritchard","year":"2012","journal-title":"Drug Resist Updat."},{"issue":"3","key":"pcbi.1013417.ref035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The Toxicity Of Poisons Applied Jointly1","volume":"26","author":"CI Bliss","year":"1939","journal-title":"Annals of Applied Biology."},{"issue":"6","key":"pcbi.1013417.ref036","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"S LOEWE","year":"1953","journal-title":"Arzneimittelforschung."},{"issue":"7","key":"pcbi.1013417.ref037","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1535-7163.MCT-23-0642","article-title":"Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism","volume":"23","author":"SC Patterson","year":"2024","journal-title":"Mol Cancer Ther."},{"issue":"1925","key":"pcbi.1013417.ref038","first-page":"20192454","article-title":"Optimizing adaptive cancer therapy: dynamic programming and evolutionary game theory","volume":"287","author":"M Gluzman","year":"2020","journal-title":"Proc Biol Sci."},{"issue":"1","key":"pcbi.1013417.ref039","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41540-020-0136-x","article-title":"Stratification and prediction of drug synergy based on target functional similarity","volume":"6","author":"M Yang","year":"2020","journal-title":"NPJ Syst Biol Appl."},{"issue":"6","key":"pcbi.1013417.ref040","first-page":"1172","article-title":"Advances in computational approaches in identifying synergistic drug combinations","volume":"19","author":"Z Sheng","year":"2018","journal-title":"Brief Bioinform."},{"key":"pcbi.1013417.ref041","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coph.2018.07.008","article-title":"Recent advances in combinatorial drug screening and synergy scoring","volume":"42","author":"T Pemovska","year":"2018","journal-title":"Curr Opin Pharmacol."},{"issue":"1","key":"pcbi.1013417.ref042","doi-asserted-by":"crossref","first-page":"13978","DOI":"10.1038\/s41598-018-32264-x","article-title":"Analysis of racial\/ethnic representation in select basic and applied cancer research studies","volume":"8","author":"S Guerrero","year":"2018","journal-title":"Sci Rep."},{"issue":"1","key":"pcbi.1013417.ref043","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(09)70160-3","article-title":"Population-based differences in treatment outcome following anticancer drug therapies","volume":"11","author":"BB Ma","year":"2010","journal-title":"Lancet Oncol."},{"issue":"1","key":"pcbi.1013417.ref044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3349\/ymj.2013.54.1.1","article-title":"The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology","volume":"54","author":"N Saijo","year":"2013","journal-title":"Yonsei Medical Journal."},{"issue":"5","key":"pcbi.1013417.ref045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FPC.0000000000000134","article-title":"Cancer pharmacogenomics: implications on ethnic diversity and drug response","volume":"25","author":"JN Patel","year":"2015","journal-title":"Pharmacogenet Genomics."},{"issue":"15","key":"pcbi.1013417.ref046","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","article-title":"Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy","volume":"15","author":"PH O\u2019Donnell","year":"2009","journal-title":"Clin Cancer Res."},{"key":"pcbi.1013417.ref047","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing; 2023. https:\/\/www.R-project.org\/"},{"key":"pcbi.1013417.ref048","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"W Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"pcbi.1013417.ref049","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","author":"RA Irizarry","year":"2003","journal-title":"Biostatistics."},{"issue":"3","key":"pcbi.1013417.ref050","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"F Iorio","year":"2016","journal-title":"Cell."},{"issue":"9","key":"pcbi.1013417.ref051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106397","article-title":"RTCGAToolbox: a new tool for exporting TCGA Firehose data","volume":"9","author":"MK Samur","year":"2014","journal-title":"PLoS One."},{"key":"pcbi.1013417.ref052","doi-asserted-by":"crossref","unstructured":"Tusher V, Tibshirani R, Chu G. Significance analysis of microarrays applied to. 2001.","DOI":"10.1073\/pnas.091062498"},{"key":"pcbi.1013417.ref053","doi-asserted-by":"crossref","unstructured":"Pollard KS, Dudoit S, van der Laan MJ. Multiple testing procedures: the multtest package and applications to genomics. Bioinformatics and computational biology solutions using R and bioconductor. Springer; 2005. p. 249-71.","DOI":"10.1007\/0-387-29362-0_15"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1013417","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1013417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:51:30Z","timestamp":1758318690000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1013417"}},"subtitle":[],"editor":[{"given":"Marc","family":"Robinson-Rechavi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1013417","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.17.628754","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}